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OBJECTIVES We sought to demonstrate, in an appropriate animal model, that co-medication with a
transcription factor-blocking agent limits restenosis after percutaneous transluminal coronary
angioplasty (PTCA).
BACKGROUND Enhanced synthesis in the vessel wall of endothelin-1 (ET-1), a powerful co-mitogen for
vascular smooth muscle cells, appears to be one mechanism that promotes restenosis after
PTCA. Deformation-induced expression of prepro-ET-1 is governed by the transcription
factor, activator protein-1 (AP-1).
METHODS An anti-AP-1 decoy oligodeoxynucleotide (dODN) strategy was devised in which the
dODN-containing solution (20 nmol) was administered locally through a Dispatch catheter
into the coronary arteries of hypercholesterolemic minipigs at the time of PTCA (AVE-GFX
stent).
RESULTS Treatment with an AP-1 dODN, mimicking the consensus binding site of the transcription
factor, significantly reduced neointimal formation in the coronary arteries of hypercholester-
olemic minipigs (n  10 to 12), compared with vehicle-treated coronary arteries, after four
weeks of follow-up (neointimal area 2.64  0.33 vs. 4.81  1.04 mm2 [mean  SEM]; p 
0.05). This effect was maintained after eight weeks (neointimal area 2.04  0.22 mm2; n 
3) and correlated with a reduction in both nuclear translocation of AP-1 and ET-1 synthesis
in the vessel wall 48 h after PTCA (n  4). In contrast, an AP-1 mutant dODN, to which
the transcription factor does not bind, showed no effect on neointimal formation at either
time point (n  3 to 7). Moreover, a consensus dODN directed against CCAAT/enhancer
binding protein (C/EBP), another deformation-sensitive transcription factor, did not
significantly affect neointimal formation after four weeks (n  3).
CONCLUSIONS These findings demonstrate the feasibility, efficacy and specificity of the anti-AP-1 dODN
approach to the treatment of restenosis, which principally but not exclusively targets
deformation-induced ET-1 synthesis in the vessel wall. Provided that these findings can be
extrapolated to the situation of patients with coronary artery disease, the observed extent of
the inhibitory effect of the AP-1 dODN treatment suggests that this co-medication may
greatly reduce the incidence of in-stent restenosis. (J Am Coll Cardiol 2002;39:732–8)
© 2002 by the American College of Cardiology
The implantation of stents has substantially reduced the rate
of restenosis after percutaneous transluminal coronary an-
gioplasty (PTCA) (1,2). However, in 10% to 40% of
patients, restenosis still occurs, resulting in revascularization
of the target lesion in up to 20% of vessels accommodating
3.0-mm stents, and even higher rates in smaller arteries
and long lesions (3,4). Thus, restenosis contributes substan-
tially to morbidity and the costs of treating coronary artery
disease. Restenosis after coronary artery stent implantation
is characterized by extensive neointimal proliferation of
vascular smooth muscle cells (SMCs) and the formation of
extracellular matrix (5–7). Possible mechanisms resulting in
this change in SMC phenotype, from a contractile to a
synthetic state, appear to be related to an increased synthesis
of endothelin-1 (ET-1) in the vessel wall. Thus, enhanced
synthesis of ET-1 has been demonstrated to occur after
pressure trauma to the vessel wall in experimental models
and in humans (8,9).
Previous work from our group has shown that this effect
occurs at the level of transcription of the prepro-ET-1 gene
(ppET-1) and that a decoy oligodeoxynucleotide (dODN)
directed against the transcription factor activator protein-1
(AP-1) inhibits both ppET-1 expression and ET-1 synthe-
sis in cultured endothelial cells exposed to mechanical
deformation, as well as in isolated, perfused, endothelium-
intact blood vessels in response to a supraphysiologic in-
crease in perfusion pressure (10). Although there are many
genes whose expression may be affected by this transcription
factor, only a few, such as ppET-1, are sensitive to defor-
mation, and there are only a few in which AP-1 functions as
an essential component of the transcription initiation com-
plex.
To verify the therapeutic potential of this dODN ap-
proach, we have investigated whether a single administra-
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tion of AP-1 consensus dODN at the time of PTCA can
limit neointimal proliferation in a coronary stent angioplasty
model in hypercholesterolemic minipigs.
METHODS
Decoy ODN technique. Double-stranded dODN (0.4
mmol/l) was prepared from complementary single-stranded
phosphorothioate-bonded ODN obtained from Eurogentec
(Ko¨ln, Germany), by melting it at 95°C for 5 min, followed
by a cool-down phase of 3 to 4 h at an ambient temperature.
After that, the solutions were split into 50 l aliquots and
frozen at 80°C until further use. The efficiency of the
hybridization reaction was verified with 2.5% agarose gel
electrophoresis and usually exceeded 98%. The sequences of
the dODN for AP-1, CCAAT/enhancer binding protein
(C/EBP) and the corresponding mutant dODN were as
follows (underlined letters denote phosphorothioate-
bonded bases; bold letters denote the core binding sequence
for the transcription factor; and italic letters denote the
mutated bases; cons  consensus dODN; mut  mutant
dODN):
AP-1cons: 5-CGCTTGATGACTCAGCCGGAA-3
3-GCGAACTACTGAGTCGGCCTT-5
AP-1mut: 5-CGCTTGATTACTTAGCCGGAA-3
3-GCGAACTAATGAATCGGCCTT-5
C/EBPcons: 5-TGCAGATTGCGCAATCTGCA-3
3-ACGTCTAACGCGTTAGACGT-5
C/EBPmut: 5-TGCAGAGACTAGTCTCTGCA-3
3-ACGTCTCTGATCAGAGACGT-5
Before infusion, an aliquot of the dODN solution (50 l)
was defrosted and diluted in 10 ml phosphate-buffered
saline (PBS; 2 mol/l final concentration). As buffer control
(vehicle), a corresponding volume of TEN (Tris, EDTA
and Nacl) buffer (10 mmol/l Tris-HCl, 1 mmol/l EDTA
and 150 mmol/l NaCl, at pH 7.5) was diluted in 10 ml PBS.
Animal model. Animal experiments were done in accor-
dance with the guidelines of the local Committee on
Animal Welfare and approved by the local authorities. The
experimental model has been described in detail previously
(11,12). Briefly, in 22 minipigs under general anesthesia,
PTCA was performed through a carotid artery. Per animal,
two or three coronary artery segments of a slightly smaller
diameter (0.3 to 0.5 mm less) than the 3.0-mm stent-
carrying balloon were chosen for treatment, as indicated
subsequently. This resulted in placement of stents more
distally in some vessels and more proximally in other vessels,
depending on their size. Operators had no knowledge of the
treatment given to a specific vessel segment (dODN or
vehicle). Before PTCA, 0.2 mg of intracoronary nitroglyc-
erin was administered. Stents (AVE-GFX, Medtronic,
Du¨sseldorf, Germany) 12 mm in length were implanted at
16 atm of pressure for 20 s. The balloons were withdrawn,
and a Dispatch catheter (Interventional Techniques, San
Diego, California, through Cardiologic, Munich, Germany)
was advanced into the stented segment and inflated to
6 atm, and infusion of the dODN solution or vehicle was
started.
The Dispatch catheter has an inner lumen allowing for
peripheral perfusion during inflation. Flow through this
inner lumen was verified in 5-min intervals. On inflation, a
helical-like–shaped balloon creates a space between the
vessel wall and the catheter, into which there is drainage
through multiple end holes of the infusion line. There is a
slow, distal run-off into the artery, allowing for continuous
drug infusion. After the desired volume (10 ml at
0.5 ml/min; corresponding to a total amount of 20 nmol
dODN) was infused, the balloon was deflated and with-
drawn, the carotid artery was ligated, and the neck wound
was closed. The animals were returned to their cages until
after the planned follow-up period (see subsequently), when
they were euthanized.
Morphometric analysis. After four or eight weeks of
follow-up, a thoracotomy under deep anesthesia was per-
formed, and the animals were euthanized by an overdose of
barbiturate. The hearts were excised and immediately per-
fused with PBS at a pressure of 100 mm Hg, followed by
perfusion-fixation with buffered 4% formaldehyde
(1,000 ml). The angioplasty segments were then excised and
embedded in methylmethacrylate. Three sections per
12-mm segment were subsequently analyzed morpho-
metrically using a digital microscopic video camera and the
Image Pro software (version 2.0, Media Cybernetics, Silver
Spring, Maryland). Areas of the lumen, neointima, media
and adventitia, as well as neointimal thickness over each
stent strut, were measured. Penetration of each strut into
the vessel wall was graded using a modified injury score, as
originally described by Schwartz et al. (13), where injury
ranged in increments from 1 (superficial) to 4 (into the
adventitia). The investigator had no knowledge of the
treatment of the segments during morphometry.
Endothelin-1 immunohistochemistry. For immunohisto-
chemical analysis, the angioplasty segments were excised
immediately after euthanasia 48 h after PTCA; the stents
were removed; and a 3-mm portion was fixed in formalde-
hyde and embedded in paraffin. The remaining portion was
deep-frozen in liquid nitrogen for subsequent electro-
phoretic mobility shift analysis. Of the paraffin blocks,
5-m-thick sections were cut and mounted on siliconized
Abbreviations and Acronyms
AP-1  activator protein-1
C/EBP  CCAAT/enhancer binding protein
dODN  decoy oligodeoxynucleotide
ETA  endothelin A
ET-1  endothelin-1
PBS  phosphate-buffered saline
ppET-1  prepro-endothelin-1
PTCA  percutaneous transluminal coronary
angioplasty
SMC  smooth muscle cell
733JACC Vol. 39, No. 4, 2002 Buchwald et al.
February 20, 2002:732–8 AP-1 Decoy Oligodeoxynucleotide and Restenosis
slides. After deparaffinization and dehydration, the sections
were first stained with hematoxylin, followed by overnight
incubation at 4°C with a mouse monoclonal anti-ET-1
antibody (Dianova, Hamburg, Germany) at a dilution of
1:250. For detection of the bound primary antibody, the
Histostain Plus kit (Zymed, San Francisco, California) was
used, comprising a biotinylated goat–anti-mouse,
streptavidin-peroxidase conjugate and the chromogenic
substrate 3-amino-9-ethylcarbazol (AEC), yielding a red
deposit.
Electrophoretic mobility shift analysis. Nuclear extracts
from the coronary artery segments were prepared as de-
scribed previously for rabbit blood vessels (14). The double-
stranded gel shift oligonucleotides (Santa Cruz Biotech-
nology, Heidelberg, Germany) for AP-1 and C/EBP
(sequences identical to AP-1cons and C/EBP dODN, as
described earlier) were end-labeled with (-32P)adenosine
triphosphate by using the 5 end-labeling kit from Amer-
sham Pharmacia Biotech (Freiburg, Germany). Typically,
the binding mixture contained 5 g of nuclear extract,
20,000 cpm of the 32P-labeled oligonucleotide probe
(0.5 ng), 1 g poly(d[I-C]) and 1.33 mmol/l of DL-
dithiothreitol in a total volume of 15 l binding buffer.
Treatment groups and statistical analysis. Angioplasty of
three coronary arteries per animal was performed in six
minipigs, with a follow-up period of four weeks (compari-
sons of vehicle, AP-1 consensus dODN and AP-1 mutant
dODN, n  3; comparisons of vehicle, C/EBP consensus
dODN and C/EBP mutant dODN, n  3), and of two
coronary arteries per animal in 16 minipigs, with a
follow-up period of 48 h (comparison of vehicle and AP-1
consensus dODN, n  4), four weeks (comparison of
vehicle and AP-1 consensus dODN, n 5; AP-1 consensus
dODN vs. AP-1 mutant dODN, n  4) or eight weeks
(comparison of AP-1 consensus dODN and AP-1 mutant
dODN, n  3).
Statistical analysis. The results are expressed as the mean
value  SEM, with n referring to the number of coronary
arteries analyzed per treatment group, regardless of compar-
isons made in individual animals. Statistical analysis using
InStat software, version 3.0 (GraphPad, San Diego, Cali-
fornia) was performed by Kruskal-Wallis one-way analysis
of variance, followed by Dunn’s post test for selected groups
or the unpaired t test with the Welch correction, as
appropriate (comparisons of three or two treatment groups,
respectively), with p  0.05 considered as statistically
significant.
RESULTS
Serum cholesterol level. Animals were fed a standard diet
supplemented with 2% cholesterol and 10 g/day of sodium
cholate for at least eight weeks before PTCA, because in a
previous study (11), cholesterol levels remained stable there-
after. This resulted in an increase in serum cholesterol from
69.4  19.4 mg/dl at baseline to 211.3  42.6 mg/dl at the
time of PTCA (n  22).
Effect of the AP-1 consensus dODN on ET-1 synthesis.
In a separate series of experiments, immunohistochemical
analysis of coronary arteries harvested at 2, 3, 4, 7, 14 and 28
days after stent placement (n  3 per time point) revealed
positive ET-1 staining, beginning at day 2 and reaching a
maximum at day 4; after 28 days, all segments stained
negative (A. B. Buchwald, unpublished observation).
Hence, ET-1 synthesis in this model starts early after
PTCA and subsides after approximately two weeks.
As shown in Figure 1, in AP-1 consensus dODN-treated
segments, ET-1 was hardly detectable 48 h after PTCA. In
contrast, there was a distinct ET-1 immunoreactivity in
vehicle-treated segments, showing particularly intense
staining in the periluminal cell layers.
Figure 1. Immunohistochemical detection of endothelin-1 (ET-1) in the coronary arteries of the same animal treated with (a) vehicle or (b) the activator
protein-1 (AP-1) consensus decoy oligodeoxynucleotide (dODN) 48 h after percutaneous transluminal coronary angioplasty. Positive immunoreactivity for
ET-1, both in the periluminal cell layers and in the media, is markedly reduced in the AP-1 consensus dODN-treated artery (original 400, before 00%
reduction). The results shown are representative of those obtained with four different animals.
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Transcription factor activation. Electrophoretic mobility
shift analysis revealed that the AP-1 consensus dODN
completely prevented nuclear translocation of AP-1 in
endothelium-intact, in vitro porcine coronary artery seg-
ments that had been exposed to 1 mol/l of phorbol
dibutyrate to upregulate AP-1 activity through stimulation
of protein kinase C (Fig. 2a). In contrast, the AP-1 mutant
dODN did not affect AP-1 abundance in the nucleus under
these conditions.
Treatment of the coronary arteries with AP-1 consensus
dODN in vivo resulted in a markedly reduced AP-1 activity
in the vessel wall 48 h after PTCA, compared with the
vehicle-treated coronary artery from the same animal (Fig.
2b). Treatment with AP-1 dODN, in contrast, had no
effect on the nuclear translocation of C/EBP and -, two
deformation-sensitive members of the C/EBP family of
transcription factors (10).
Proliferative vessel wall response with dODN treatment.
Injury scores in AP-1 consensus and AP-1 mutant dODN-
treated arteries (range 2.0 to 2.1) were comparable to those
in the buffer control group (Table 1). Figure 3 displays the
morphometric analysis of a typical experiment with three
different coronary arteries from the same animal treated
with either vehicle, AP-1 consensus dODN or AP-1
mutant dODN. Of note, the AP-1 consensus dODN
treatment had a pronounced effect on neointimal prolifera-
tion, despite comparable injury in all three arteries. After
four weeks of follow-up, the minimal lumen area was clearly
larger and the neointimal area was significantly smaller in
AP-1 consensus dODN-treated segments than in vehicle-
Figure 2. (a) The effects of pretreatment (1 h) with activator protein-1 (AP-1) consensus (AP-1 cons) or AP-1 mutant (AP-1 mut) decoy
oligodeoxynucleotide (dODN) (10 mol/l each) on phorbol dibutyrate (1 mol/l)-induced nuclear translocation of AP-1 in endothelium-intact segments
of the porcine left anterior descending coronary artery from the same animal. The segments were incubated in Waymouth medium containing 10% fetal
bovine serum for 1 h at 37°C, followed by electrophoretic mobility shift analysis. The results shown are representative of at least two further experiments
with segments from different animals. (b) In vivo treatment of porcine coronary arteries from the same animal, with AP-1 consensus dODN resulting in
a diminished nuclear translocation of AP-1 relative to the buffer control 48 h after percutaneous transluminal coronary angioplasty (upper box), although
nuclear translocation of CCAAT/enhancer binding protein (C/EBP) and - was not affected. The results shown are representative of those obtained with
four different animals. Identification of the C/EBP family members was done by supershift analysis (10).
Table 1. Histologic and Morphometric Analysis of the Effects of the Different dODN in the Coronary Angioplasty Model
Buffer
(n  10)
AP-1 cons
(n  12)
AP1-21 mut
(n  7)
C/EBP cons
(n  3)
C/EBP mut
(n  3)
AP-1 cons
(n  3)
AP-1 mut
(n  3)
Follow-up (weeks) 4 4 4 4 4 8 8
Injury score 2.07  0.06* 2.08  0.04 2.03  0.03 2.34  0.19 2.27  0.14 1.99  0.02 2.09  0.06
Minimal lumen area (mm2) 3.78  0.70† 5.61  0.63 4.78  0.74 2.39  0.95 4.62  0.88 2.78  0.57 3.38  0.48
Percent area stenosis 86.2  9.1† 32.5  2.2 49.4  6.3 87.6  8.0 69.7  7.6 43.4  2.3 69.5  11.5
Medial area (mm2) 1.72  0.19* 1.89  0.21 2.12  0.17 2.01  0.04 2.34  0.15 1.63  0.05 1.30  0.19
Adventitial area (mm2) 2.57  0.59* 1.50  0.27 3.14  0.81 4.77  0.92 5.37  0.73 1.15  0.14 1.58  0.21
Total vessel area (mm2) 14.10  1.58* 12.32  1.19 15.22  1.35 19.68  2.14 20.49  1.61 8.00  0.75 9.87  0.32
*p  NS versus all other groups. †p  0.05 versus AP-1 cons. Data are presented as the mean value  SEM, except for follow-up. n denotes the number of coronary arteries
analyzed (mean of 3 sections/stent) per treatment group. Note that due to destruction of 1 buffer control-treated segment before embedding in methylmethacrylate, the number
of segments in this group is 10 instead of 11.
AP-1  activator protein-1; AP-1 cons  AP-1 consensus dODN; AP-1 mut  AP-1 mutant dODN; C/EBP  CCAAT/enhancer binding protein consensus dODN;
C/EBP mut  C/EBP mutant dODN; dODN  decoy oligonucleotide.
735JACC Vol. 39, No. 4, 2002 Buchwald et al.
February 20, 2002:732–8 AP-1 Decoy Oligodeoxynucleotide and Restenosis
treated or AP-1 mutant dODN-treated segments (Fig. 4).
The media and total vessel area were comparable between
the treatment groups. There was no evidence of decreased
cellularity in the media in any of the treatment groups, as an
indicator of potential toxic induction of fibrosis or calcifi-
cation (Table 1).
This effect of AP-1 consensus dODN, as well as its
effects on the adventitial, luminal (Table 1) and neointimal
area (Fig. 5a), were maintained at eight weeks after PTCA,
compared with AP-1 mutant dODN. No comparison with
the buffer control group was made at this point in time, as
previous studies with the minipig model have shown that
neointimal formation manifests at four weeks and does not
progress or regress over the following eight weeks (11).
To confirm that AP-1 consensus dODN exerts a specific
effect that cannot be mimicked by a dODN directed against
another transcription factor that is also deformation-
sensitive and involved in the regulation of ppET-1 expres-
sion in another species (rabbit carotid artery [10]), the
effects of C/EBP consensus dODN on restenosis four weeks
after PTCA were investigated as well. However, both the
consensus and corresponding mutant dODN did not inhibit
neointimal formation, compared with vehicle-treated seg-
ments (Table 1, Fig. 5b).
DISCUSSION
Study findings. The main findings obtained in the minipig
angioplasty model can be summarized as follows. Infusion
of dODN against the transcription factor AP-1, using a
local drug delivery catheter, results in a profound decrease in
AP-1 activity and marked suppression of intravascular ET-1
synthesis 48 h after PTCA. This, in turn, contributes to a
significant reduction of neointimal proliferation as the
major determinant of in-stent restenosis, compared with
buffer as the control, by 50% after four weeks. The
corresponding mutant dODN, in contrast, has no effect.
Moreover, inhibition of proliferation is maintained after
eight weeks, indicating a definitive effect, not merely a delay
of proliferation, occurring later than that in control arteries.
The effect is achieved by a single application of the “naked”
dODN at the time of PTCA, with no further treatment.
Role of ET-1 in in-stent restenosis. The action of ET-1
has been previously suggested as an important contributor to
Figure 3. The proliferative vessel wall response four weeks after stent angioplasty in three coronary arteries from the same animal infused with vehicle (a),
activator protein-1 (AP-1) consensus decoy oligodeoxynucleotide (dODN) (b) or AP-1 mutant dODN (c). Extensive proliferation in (a) and (c) is
markedly reduced in the AP-1 consensus dODN-infused artery (elastica–van Gieson staining, original 40, before 00% reduction).
Figure 4. A comparison of the effects of activator protein-1 (AP-1) consensus (AP-1 cons) decoy oligodeoxynucleotide (dODN), AP-1 mutant (AP-1 mut)
dODN and buffer control on neointimal area (a) and lumen area (b), expressed as the percentage of the in-stent area four weeks after percutaneous
transluminal coronary angioplasty. *p  0.05 vs. buffer control. †p  0.05 vs. AP-1 mutant dODN.
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post-PTCA restenosis. Tissue ET-1 levels increase after
endothelial denudation in a rabbit carotid artery model (8),
and ET-1 is released from human atherosclerotic coronary
arteries after injury (9). Selective antagonism of the endo-
thelin A (ETA) receptor reduced the proliferative vessel wall
response in a rat carotid artery (15) and a porcine femoral
and carotid artery PTCA model (16), in accordance with
the findings of this study. Similarly, the approach of
selective ETA receptor antagonism in a non-
hypercholesterolemic porcine coronary stent angioplasty
model reduced neointimal hyperplasia (17). However, a
successful reduction in proliferation was observed, with
modest proliferation in the control/placebo groups (e.g.,
average neointimal thickness of 0.45 mm in the study by
McKenna et al. (17) vs. 1.03 mm in the present study). In
contrast, in this study, inhibition of ET-1 synthesis by the
AP-1 dODN limited neointimal proliferation, irrespective
of the degree of arterial injury. Moreover, this effect was
achieved with a single periprocedural local infusion of
dODN, while antagonizing the receptor-required systemic
administration of the drug over several days.
Vessel wall trauma and therapeutic efficacy. The prolif-
erative vessel wall response increases with increasing stretch,
and thus injury to the vessel wall with PTCA (12,13). In
accordance with the available evidence suggesting stretch-
induced activation of ET-1 synthesis as a major determinant
of the proliferative vessel wall response to injury, exceeding
the adaptive proliferation secondary to mild stretch, the
results of the present study support the hypothesis that
inhibition of ppET-1 gene expression and, consequently,
the synthesis of mature ET-1 results in a limited prolifer-
ative response, even in areas of deep vessel wall injury.
Specificity of the dODN approach. It could be argued
that any mechanosensitive transcription factor can cause
neointimal proliferation after PTCA, especially if this tran-
scription factor is potentially associated with the expression
of the target gene, too (10). However, the negative results
obtained in the animals treated with the C/EBP dODN
indicate that the proliferative response in this model is
specifically mediated by AP-1. This does not mean, how-
ever, that the inhibitory effect of AP-1 dODN on in-stent
restenosis is solely due to the blockade of deformation-
induced ppET-1 expression. Other gene products involved
in neointimal formation, the expression of which is influ-
enced by AP-1, may be likewise affected, although from a
therapeutic point of view, this does not necessarily pose a
problem.
Clinical perspective. Given that the aforementioned re-
sults can be extrapolated to the situation in patients with
coronary artery disease, the observed extent of the inhibitory
action of dODN treatment suggests that this co-medication
may greatly reduce the incidence of in-stent restenosis,
which at present ranges from 10% to 40% after six months.
Study limitations. A potential limitation of this study is
that it was performed in minipigs, and although these
animals were fed an atherogenic diet, PTCA was performed
in near-healthy coronary arteries. In the clinical situation,
severe atherosclerosis and calcification, replacing parts of the
normal vessel wall, may influence the role of the endothelin
system in the reparative response after PTCA (9). Although
the release of ET-1 from human coronary arteries after
PTCA suggests a role for the peptide in human atheroscle-
rosis, as well, the dODN approach must be tested in a
clinical setting.
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